Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Target Price at $244.64

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus rating of “Moderate Buy” by the sixteen brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $248.2857.

Several equities analysts recently issued reports on ASND shares. UBS Group reissued a “buy” rating and set a $307.00 price target (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Royal Bank Of Canada raised their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Friday, September 5th.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Perceptive Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth approximately $166,367,000. T. Rowe Price Investment Management Inc. grew its position in shares of Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock worth $475,970,000 after buying an additional 328,278 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $51,029,000. RA Capital Management L.P. boosted its stake in Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock worth $1,602,474,000 after acquiring an additional 168,752 shares during the last quarter. Finally, Braidwell LP bought a new position in Ascendis Pharma A/S during the 1st quarter worth approximately $16,632,000.

Ascendis Pharma A/S Stock Down 0.5%

Shares of ASND stock opened at $208.43 on Friday. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $216.45. The company has a market capitalization of $12.86 billion, a P/E ratio of -40.39 and a beta of 0.41. The firm has a 50-day moving average price of $197.51 and a 200 day moving average price of $176.27.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. As a group, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.